3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Lung Neoplasms
1
Lung Diseases
1
Interventions
pembrolizumab
130
Carboplatin
127
Cisplatin
118
Paclitaxel
99
Gemcitabine
87
Specimen Handling
80
Magnetic Resonance Spectroscopy
80
Docetaxel
70
Dexamethasone
62
Cyclophosphamide
61
Pemetrexed
59
Capecitabine
56
Bevacizumab
56
durvalumab
52
Oxaliplatin
52
Fluorouracil
50
Doxorubicin
49
Radiotherapy
48
Leucovorin
45
Radiation
44
Rituximab
43
Lenalidomide
42
Vincristine
39
Etoposide
36
Nivolumab
34
atezolizumab
33
Letrozole
32
130-nm albumin-bound paclitaxel
32
Irinotecan
31
Prednisone
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
zipalertinib
×
90 days
×
Clear all
NCT07128199
2026-05-05
REZILIENT4
Taiho Oncology, Inc.
Phase 3
Active not recruiting
360 enrolled
NCT05973773
2026-03-10
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled